NPS31807, a Standardized Extract from Sphaeranthus indicus, Inhibits Inflammatory, Migratory and Proliferative Activity in Keratinocytes and Immune Cells

Debarshi Chakrabarti, Ashish Suthar, Gurunathan Jayaraman, Bhaskaran Muthuvelan, Somesh Sharma, Muralidhara Padigaru

Department of Biomarker Discovery, Piramal Life Sciences India Limited, Mumbai, India.
Department of Herbal Development, Piramal Life Sciences India Limited, Mumbai, India.
School of Biosciences and Technology, VIT University, Vellore, India.

DOI: 10.4236/pp.2012.32025                

Abstract

Chronic inflammation induced hyper-proliferation, and migration of keratinocytes are pathological hallmarks of psoriasis. Extracts from Sphaeranthus spp. demonstrate pharmacological activity in-vitro and in-vivo. However, the activity in modulating disease relevant pathways in psoriasis has not been reported. In the current study, a standardized herbal extract from Sphaeranthus indicus (NPS31807) was used to study the mechanistic activity under conditions of inflammation, keratinocyte proliferation and migration using cell based and gene expression assays. NPS31807 treatment reduced levels of pro-inflammatory cytokines from human macrophages and activated epidermal keratinocytes in a dose dependent manner. Treatment with NPS31807 diminished NFκB and AP-1 transcription activity in human macrophages. Lowered nuclear translocation of p65 sub-unit in macrophages by treatment confirmed reduced activity of NFκB. Gene expression profiling showed attenuated expression of genes involved with inflammation such as TNF signaling, and angiogenesis by NPS31807. Inhibition of angiogenesis and matrix metalloproteinase production in keratinocytes was confirmed using RTq-PCR assays. Pretreatment with NPS31807 led to significant reduction of STAT3 phosphorylation and mitogen induced cellular migration. NPS31807 induced inhibition of proliferative genes and BrdU uptake in epidermal keratinocytes. In summary, our study provides novel molecular insights into the anti-inflammatory, anti-migratory and anti-proliferative properties of NPS31807. In summary, NPS31807, an extract from Sphaeranthus indicus can be used as therapeutic option in inflammatory and auto-immune conditions such as psoriasis.

Keywords

Herbal Extract; Cytokine; Psoriasis; NPS31807; Keratinocyte; Sphaeranthus; Phytopharmaceutical

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	H. Wagner, “Synergy Research: Approaching a New Generation of Phytopharmaceuticals,” Fitoterapia, Vol. 82, No. 4, 2011, pp. 34-37. doi:10.1016/j.fitote.2010.11.016
[2]	V. J. Galani, B. G. Patel and D. G. Rana, “Sphaeranthus Indicus Linn: A Phytopharmacological Review,” International Journal of Ayurveda Research, Vol. 1, No. 4, 2009, pp. 247-253. doi:10.4103/0974-7788.76790
[3]	A. Shirwaikar, K. S. Prabhu and I. S. Punitha, “In Vitro Antioxidant Studies of Sphaeranthus indicus (Linn),” Indian Journal of Experimental Biology, Vol. 44, No. 12, 2006, pp. 993-996.
[4]	A. Jain and E. Basal, “Inhibition of Pro-pionibacterium Acnes-Induced Mediators of Inflammation by Indian Herbs,” Phytomedicine, Vol. 10, No. 1, 2003. pp. 34-38. doi:10.1078/094471103321648638
[5]	F. Sadaf, R. Saleem, M. Ahmed, S. I. Ahmad and Z. Navaid-Ul, “Healing Potential of Cream Containing Extract of Sphaeranthus indicus on Dermal Wounds in Guinea Pigs,” Journal of Ethnopharmacology, Vol. 107, No. 2, 2006, pp. 161-163. doi:10.1016/j.jep.2006.02.022
[6]	M. P. Schon and W. H. Boehncke, “Psoriasis,” New England Journal of Medicine, Vol. 352, 2005, pp. 1899-1912. doi:10.1056/NEJMra041320
[7]	D. J. Marble, K. B. Gordon and B. J. Nickoloff, “Targeting TNFα Rapidly Reduces Density of Dendritic Cells and Macrophages in Psoriatic Plaques with Restoration of Epidermal Keratinocyte Differentiation,” Journal of Dermatological Science, Vol. 48, No. 2, 2007, pp. 87-101. doi:10.1016/j.jdermsci.2007.06.006
[8]	M. Tomic-Canic, M. Komine, I. M. Freedberg and M. Blumenberg, “Epidermal Signal Transduction and Transcription Factor Activation in Activated Keratinocytes,” Journal of Dermatological Science, Vol. 17, No. 3, 1998, pp. 167-181. doi:0.1016/S0923-1811(98)00016-4
[9]	U. Chaudhari, P. Romano, L. D. Mulcahy, L. T. Dooley, D. G. Baker and A. B. Gottlieb, “Efficacy and Safety of Infliximab Monotherapy for Plaque-Type Psoriasis: A Randomised Trial,” Lancet, Vol. 357, No. 9271, 2001, pp. 1842-1847. doi:10.1016/S0140-6736(00)04954-0
[10]	A. B. Gottlieb, “Etanercept for the Treatment of Psoriasis and Psoriatic Arthritis,” Dermatology and Therapy, Vol. 17, 2004, pp. 401-408. doi:10.1016/S0140-6736(00)02530-7
[11]	A. B. Gottlieb, F. Chamian, S. Masud, I. Cardinale, M. V. Abello, M. A. Lowes, F. Chen, M. Magliocco and J. G. Krueger, “TNF Inhibition Rapidly Down-Regulates Multiple Pro-inflammatory Pathways in Psoriasis Plaques,” The Journal of Immunology, Vol. 175, No. 4, 2005, pp. 2721-2729.
[12]	R. Bissonnette, V. Ho and R. G. Langley, “Safety of Con- ventional Systemic Agents and Biologic Agents in the Treatment of Psoriasis,” Journal of Cutaneous Medicine and Surgery, Vol. 13, Suppl. 2, 2009, pp. 67-76.
[13]	S. Amladi, C. Nayak, R. Torsekar, V. Vishalakshi, U. Khopkar, V. Saraf, S. Kulkarni, A. Shindikar, A. Patil, S. Patil, H. Parikh, A. Suthar, V. Chauhan, M. Padigaru, D. Chakrabarti and S. Sharma, “Sphaeranthus indicus (East Indian Globe Thistle)—A Promising Natural Remedy for Psoriasis,” Program of the 68th Annual Meeting of the American Academy of Dermatology, 2010.
[14]	L. C. Fonseca, S. S. Dadarkar, A. S. Lobo, A. C. Suthar, V. S. Chauhan, S. Chandrababu, S. D. Sharma, N. M. Dagia and M. Padigaru, “7-Hydroxyfrullanolide, a Sesquiterpene Lactone, Inhibits Pro-Inflammatory Cytokine Production from Immune Cells and Is Orally Efficacious in Animal Models of Inflammation,” European Journal of Pharmacology, Vol. 644, No. 1-3, pp. 220-229. doi:10.1016/j.ejphar.2010.06.052
[15]	D. C. Rio, M. Ares Jr., G. J. Hannon and T. W. Nilsen, “Purification of RNA Using TRIzol (TRI Reagent),” Cold Spring Harbor Protocols, Vol. 10, No. 6, 2010. doi:10.1101/pdb.prot5439
[16]	A. Khanna, K. Mahalingam, D. Chakrabarti and G. Periyasamy, “Ets-1 Expres-sion and Gemcitabine Chemoresistance in Pancreatic Cancer Cells,” Cellular & Molecular Biology Letters, Vol. 16, No. 1, 2011, pp. 101-113. doi:10.2478/s11658-010-0043-z
[17]	S. Rozen and H. Skaletsky, “Primer3 on the WWW for General Users and for Biologist Programmers,” Methods in Molecular Biology, Vol. 132, No. 3, 2000, pp. 365- 386.
[18]	K. J. Livak and T. D. Schmittgen, “Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2(-Delta Delta C(T)) Method,” Methods, Vol. 25, No. 4, 2001, pp. 402-408. doi:10.1006/meth.2001.1262
[19]	E. Staub, J. Groene, M. Heinze, D. Mennerich, S. Roep- cke, I. Klaman, B. Hinzmann, E. Castanos-Velez, C. Pilarsky, B. Mann, T. Brummendorf, B. Weber, H. J. Buhr and A. Rosenthal, “Genome-Wide Expression Patterns of Invasion Front, Inner Tumor Mass and Surrounding Normal Epithelium of Colorectal Tumors,” Molecular Cancer, Vol. 6, No. 1, 2007, p. 79. doi:10.1186/1476-4598-6-79
[20]	H. Mi and P. Thomas, “PANTHER Pathway: An Ontol- ogy-Based Pathway Database Coupled with Data Analy- sis Tools,” Methods in Molecular Biology, Vol. 563, Part 2, 2009, pp. 123-140. doi:10.1007/978-1-60761-175-2_7
[21]	A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, J. P. Mesirov, “Gene Set En- richment Analysis: A Knowledge-Based Approach for Interpreting Ge-nome-Wide Expression Profiles,” Pro- ceedings of the National Academy of Sciences of the United States of America, Vol. 102, No. 43, 2005, pp. 15545-15550. doi:10.1073/pnas.0506580102
[22]	P. M. Campeau, M. Rafei, M. N. Boivin, Y. Sun, G. A. Grabowski and J. Galipeau, “Characterization of Gaucher Disease Bone Mar-row Mesenchymal Stromal Cells Reveals an Altered Inflammatory Secretome,” Blood, Vol. 114, No. 15, 2009, pp. 3181-3190. doi:10.1182/blood-2009-02-205708
[23]	F. Liang, J. Liang, W. Q. Wang, J. P. Sun, E. Udho and Z. Y. Zhang, “PRL3 Promotes Cell Invasion and Proliferation by Down-Regulation of Csk Leading to Src Activation,” The Journal of Biological Chemistry, Vol. 282, No. 8, 2007, pp. 5413-5419. doi:10.1074/jbc.M608940200
[24]	L. C. Fonseca, S. S. Dadarkar, A. S. Lobo, P. B. Mishra, A. D. Thakkar, S. Chandrababu and M. Padigaru, “NF- KappaB-Mediated Anti-Inflammatory Activity of the Sesquiterpene Lactone 7-Hydroxyfrullanolide,” European Journal of Pharmacology, Vol. 657, No. 1-3, pp. 41-50. doi:10.1016/j.ejphar.2011.01.050
[25]	T. Banno, A. Gazel and M. Blumenberg, “Effects of Tu- mor Necrosis Factor-Alpha (TNF Alpha) in Epidermal Keratinocytes Revealed Using Global Transcriptional Profiling,” The Journal of Biological Chemistry, Vol. 279, No. 31, 2004, pp. 32633-32642. doi:10.1074/jbc.M400642200
[26]	J. Raingeaud and J. Pierre, “Interleukin-4 Downregulates TNFα-Induced IL-8 Production in Keratinocytes,” FEBS Letters, Vol. 579, No. 18, 2005, pp. 3953-3959. doi:10.1016/j.febslet.2005.06.019
[27]	B. J. Nickoloff, R. S. Mitra, J. Varani, V. M. Dixit and P. J. Polverini, “Aberrant Production of Interleukin-8 and Thrombospondin-1 by Psoriatic Keratinocytes Mediates Angiogenesis,” American Journal of Pathology, Vol. 144, No. 4, 1994, pp. 820-828.
[28]	H. Mizutani, Y. Ohmoto, T. Mizutani, M. Murata and M. Shimizu, “Role of Increased Production of Monocytes TNF-α, IL-1β and IL-6 in Psoriasis: Relation to Focal Infection, Disease Activity and Responses to Treatments,” Journal of Dermatological Science, Vol. 14, No. 2, 1997, pp. 145-153. doi:10.1016/S0923-1811(96)00562-2
[29]	K. Boniface, C. Diveu, F. Morel, N. Pedretti, J. Froger, E. Ravon, M. Garcia, E. Venereau, L. Preisser, E. Guignouard, G. Guillet, G. Dagregorio, J. Pene, J. P. Moles, H. Yssel, S. Chevalier, F. X. Bernard, H. Gascan and J. C. Lecron, “Oncostatin M Secreted by Skin Infiltrating T Lymphocytes Is a Potent Keratinocyte Activator Involved in Skin Inflammation,” The Journal of Immunology, Vol. 178, No. 7, 2007, pp. 4615-4622.
[30]	T. Nukui, R. Ehama, M. Sakaguchi, H. Sonegawa, C. Katagiri, T. Hibino and N. H. Huh, “S100A8/A9, a Key Mediator for Positive Feedback Growth Stimulation of Normal Human Keratinocytes,” Journal of Cellular Biochemistry, Vol. 104, No. 2, 2008, pp. 453-464. doi:10.1002/jcb.21639
[31]	B. Adzu, S. Amos, S. D. Kapu and K. S. Gamaniel, “Anti- Inflammatory and Anti-Nociceptive Effects of Sphaeranthus senegalensis,” Journal of Ethnopharmacology, Vol. 84, No. 2-3, 2003, pp. 169-173. doi:10.1016/S0378-8741(02)00295-7
[32]	U. R. Atta, M. S. Shekhani, S. Perveen, U. R. Habib, A. Yasmin, A. Z. Haque and D. Shaikh, “7-Hydroxyfrulla- nolide, an Anti-microbial Sesquiterpene Lactone from Sphae- ranthus indi-cus Linn,” European Journal of Pharmacol- ogy, Vol. 644, No. 1-3, 1989, pp. 220-229. doi:10.1016/j.ejphar.2010.06.052
[33]	J. S. Sohoni, S. R. Rojatkar, M. M. Kulkarni, N. N. Dhaneshwar, S. S. Tavale, T. N. Gururow and B. A. Nagasampagi, “A New Eudesmanolide and 2-Hydroxycostic Acid from Sphae-ranthus indicus Linn: X-Ray Molecular Structure of 4-α 5-α Epoxy-7-α-Hydroxyeudesmanolide,” Journal of the Chemical Society, Perkin Transactions 1, Vol. 2, 1988, pp. 157-160
[34]	S. C. Gupta, C. Sundaram, S. Reuter and B. B. Aggarwal, “Inhibiting NF-KappaB Activation by Small Molecules as a Therapeutic Strategy,” Biochimica et Biophysica Acta, Vol. 1799, No. 10-12, pp. 775-787. doi:10.1016/j.bbagrm.2010.05.004
[35]	P. F. Lizzul, A. Aphale, R. Malaviya, Y. Sun, S. Masud, V. Dombrovskiy and A. B. Gottlieb, “Differential Expression of Phosphorylated NF-KappaB/RelA in Normal and Psoriatic Epidermis and Downregulation of NF-KappaB in Response to Treatment with Etanercept,” Journal of Investigative Dermatology, Vol. 124, No. 6, 2005, pp. 1275-1283. doi:10.1111/j.0022-202X.2005.23735.x
[36]	Y. J. Na, Y. J. Jeon, J. H. Suh, J. S. Kang, K. H. Yang and H. M. Kim, “Suppression of IL-8 Gene Expression by Radicicol Is Mediated through the Inhibition of ERK1/2 and p38 Signaling and Negative Regulation of NF-KappaB and AP-1,” International Immunopharmacology, Vol. 1, No. 9-10, 2001, pp. 1877-1887. doi:10.1016/S1567-5769(01)00113-8
[37]	M. MacFar-lane, “TRAIL-Induced Signalling and Apoptosis,” Toxicology Letters, Vol. 139, No. 2-3, 2003, pp. 89-97. doi:10.1016/S0378-4274(02)00422-8
[38]	G. E. Diehl, H. H. Yue, K. Hsieh, A. A. Kuang, M. Ho, L. A. Morici, L. L. Lenz, D. Cado, L. W. Riley and A. Winoto, “TRAIL-R as a Negative Regulator of Innate Immune Cell Responses,” Immunity, Vol. 21, No. 6, 2004, pp. 877-889. doi:10.1016/j.immuni.2004.11.008
[39]	S. Peternel, L. Prpic-Massari, T. Manestar-Blazic, I. Brajac and M. Kastelan, “Increased Expression of TRAIL and Its Death Receptors DR4 and DR5 in Plaque Psoriasis,” Archives of Dermatological Research, Vol. 303, No. 6, pp. 389-397.
[40]	L. C. Zaba, J. Fuentes-Duculan, N. J. Eungdamrong, L. M, Johnson-Huang, K. E, Nograles, T. R, White, K. C, Pierson, T. Lentini, M. Suarez-Farinas, M. A. Lowes and J. G. Krueger, “Identification of TNF-Related Apoptosis-Inducing Ligand and Other Molecules that Distinguish Inflammatory from Resident Dendritic Cells in Patients with Psoriasis,” Journal of Allergy and Clinical Immunology, Vol. 125, No. 6, pp. 1261-1268. doi:10.1016/j.jaci.2010.03.018
[41]	D. J. Dauer, B. Ferraro, L. Song, B. Yu, L. Mora, R. Buettner, S. Enkemann, R. Jove and E. B. Haura, “Stat3 Regulates Genes Common to Both Wound Healing and Cancer,” Oncogene, Vol. 24, No. 21, 2005, pp. 3397-3408. doi:10.1038/sj.onc.1208469
[42]	S. Sano, K. S. Chan and J. DiGiovanni, “Impact of Stat3 Activation upon Skin Biology: A Dichotomy of Its Role between Homeostasis and Diseases,” Journal of Dermatological Science, Vol. 50, No. 1, 2008, pp. 1-14. doi:10.1016/j.jdermsci.2007.05.016
[43]	M. Kira, S. Sano, S. Takagi, K. Yoshikawa, J. Takeda and S. Itami, “STAT3 Deficiency in Keratinocytes Leads to Compromised Cell Migration through Hyperphosphoryla- tion of p130(cas),” The Journal of Biological Chemistry, Vol. 277, No. 15, 2002. pp. 12931-12936. doi:10.1074/jbc.M110795200
[44]	H. Toyoda, T. Komurasaki, D. Uchida and S. Morimoto, “Distribution of mRNA for Human Epiregulin, a Differentially Expressed Member of the Epidermal Growth Factor Family,” Biochemical Journal, Vol. 326, Part 1, 1997, pp. 69-75.
[45]	E. Sasaki, R. Pai, F. Halter, T. Komurasaki, T. Arakawa, K. Kobayashi, T. Kuroki and A. S. Tarnawski, “Induction of Cyclooxygenase-2 in a Rat Gastric Epithelial Cell Line by Epiregulin and Basic Fibroblast Growth Factor,” Journal of Clinical Gastroenterology, Vol. 27, Suppl. 1, 1998, pp. S21-S27.
[46]	D. S. Taylor, X. Cheng, J. E. Pawlowski, A. R. Wallace, P. Ferrer and C. J. Molloy, “Epiregulin Is a Potent Vascular Smooth Muscle Cell-Derived Mitogen Induced by Angiotensin II, Endothelin-1, and Thrombin,” Proceedings of the National Academy of Sciences, Vol. 96, No. 4, 1999, pp. 1633-1638. doi:10.1073/pnas.96.4.1633
[47]	T. T. Huang, S. L. Feinberg, S. Suryanarayanan and S. Miyamoto, “The Zinc Finger Domain of NEMO Is Selec- tively Required for NF-Kappa B Activation by UV Radiation and Topoisomerase Inhibitors,” Molecular and Cellular Biology, Vol. 22, No. 16, 2002, pp. 5813-5825. doi:10.1128/MCB.22.16.5813-5825.2002
[48]	J. T. Elder, “In This Issue,” Journal of Investigative Dermatology, Vol. 123, No. 2, 2004, pp. 6-7. doi:10.1111/j.0022-202X.2004.23240.x
[49]	H. Onuma, C. Mastui and M. Morohashi, “Quantitative Analysis of the Proliferation of Epidermal Cells Using a Human Skin Organ Culture System and the Effect of DbcAMP Using Markers of Proliferation (BrdU, Ki-67, PCNA),” Archives of Dermatological Research, Vol. 293, No. 3, 2001, pp. 133-138. doi:10.1007/s004030000195
[50]	M. Heenen, S. Thiriar, J. C. Noel and P. Galand, “Ki-67 Immunostaining of Normal Human Epidermis: Comparison with 3H-Thymidine Labelling and PCNA Immunostaining,” Dermatology, Vol. 197, No. 2, 1998, pp. 123-126. doi:10.1159/000017982
[51]	M. Kamsteeg, P. A. Jansen, I. M. van Vlijmen-Willems, P. E. van Erp, D. Rodijk-Olthuis, P. G. van der Valk, T. Feuth, P. L. Zeeuwen and J. Schalkwijk, “Molecular Diagnostics of Psoriasis, Atopic Dermatitis, Allergic Contact Dermatitis and Irritant Contact Dermatitis,” British Journal of Dermatology, Vol. 162, No. 3, pp. 568-578. doi:10.1111/j.1365-2133.2009.09547.x
[52]	L. Rittie, S. Kansra, S. W. Stoll, Y. Li, J. E. Gudjonsson, Y. Shao, L. E. Michael, G. J. Fisher, T. M. Johnson and J. T. Elder, “Differential ErbB1 Signaling in Squamous Cell Versus Basal Cell Carcinoma of the Skin,” The American Journal of Pathology, Vol. 170, No. 6, 2007, pp. 2089- 2099. doi:10.2353/ajpath.2007.060537